Search

Displaying results 591 - 600 of 8171 in total
  1. Drug

    Ornidazole

    go.drugbank.com/drugs/DB13026
    Investigational

    Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.

    Products: TIBERAL ROCHE DE 500 MG
  2. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CL<sup>PRO</sup>) inhibitor that is the subject of clinical trial NCT04756531. … [L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform neurofibromas (PN … NF-1 is considered rare, with an estimated incidence of 1/3000 individuals.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for

  6. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for

  7. Drug

    Thonzylamine

    go.drugbank.com/drugs/DB11235
    Approved

    Thonzylamine is an antihistamine and anticholinergic drug.

    Mixtures: Poly-Hist DM, Nasopen PE
  8. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    Sulpiride first appeared in published literature in 1967. Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher d...

    Mixtures: NEUPAX DUO-SCategories: P-glycoprotein substrates, Dopamine D2 Receptor Antagonists
  9. Drug

    Aprotinin

    go.drugbank.com/drugs/DB06692
    ApprovedInvestigationalWithdrawn

    The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery.

    Mixtures: TISSEEL FIBRIN SEALANT VH S/D (FROZEN), SAN. VE TİC. LTD.
  10. Target

    1,4-alpha-glucan-branching enzyme

    go.drugbank.com/bio_entities/BE0010808
    EnzymeHumans

    Glycogen-branching enzyme participates in the glycogen biosynthetic process along with glycogenin and glycogen synthase. … Generates alpha-1,6-glucosidic branches from alpha-1,4-linked glucose chains, to increase solubility of the glycogen polymer (PubMed:26199317, PubMed:8463281, PubMed:8613547)

    Synonyms: Glycogen-branching enzyme